Atorvastatin, valsartan, and n-acetylcysteine prevent cardiac hypertrophy and overexpression of myocardin in pressure-overloaded rat heart

Chiung Zuan Chiu, Bao Wei Wang, Kou Gi Shyu

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Background: The use of statin has emerged as a beneficial treatment for cardiac hypertrophy.Myocardin, a cardiac restricted gene, is up-regulated in the hypertrophic myocardium. However, the effect of statin on myocardin expression due to pressure overloaded cardiac hypertrophy is not well understood. Methods: To evaluate the effect of statin on myocardin expression and cardiac hypertrophy, infrarenal aortic banding was performed for 4 weeks in adult Sprague-Dawley rats to induce cardiac hypertrophy. Atorvastatin (30 mg/kg), valsartan (30 mg/kg), N-acetylcysteine (NAC; 250 mg/kg), and the above three agents combined were given daily after surgery. Results: After aortic banding for 4 weeks, the heart weight, the ratio of heart/body weight, and mean arterial pressure (MAP) increased significantly. However, echocardiography showed concentric hypertrophy after aortic banding. Elevated MAP and increased wall thickness and heart weight were reversed after treatment with atorvastatin, valsartan, NAC, and a combination of the three agents. Myocardin, myosin heavy chain (MHC), brain natriuretic peptide (BNP) proteins, myocardin mRNA, angiotensin II (AngII), and superoxide dismutase (SOD) expressions were up-regulated in the banding group, which were inhibited by atorvastatin, valsartan, NAC, and the three agents combined. Increased immunohistochemical labelings of myocardin and MHC in the ventricular myocardium were observed in the banding group, and again atorvastatin, valsartan, or NAC reversed the labelings. Conclusion: Myocardin, MHC, BNP proteins, myocardin mRNA, AngII, and SOD expressions were up-regulated in the rat model of pressure-overloaded cardiac hypertrophy. Treatment with atorvastatin, valsartan, NAC, or three agents put together is associated with a reversal of abnormal regulation of myocardin in the hypertrophic myocardium.

Original languageEnglish
Pages (from-to)286-296
Number of pages11
JournalActa Cardiologica Sinica
Volume28
Issue number4
Publication statusPublished - Dec 2012

Fingerprint

Valsartan
Acetylcysteine
Cardiomegaly
Pressure
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Myosin Heavy Chains
Myocardium
Brain Natriuretic Peptide
Angiotensin II
Superoxide Dismutase
Arterial Pressure
Atorvastatin Calcium
myocardin
Weights and Measures
Messenger RNA

Keywords

  • Aortic banding
  • Cardiac hypertrophy
  • Myocardin
  • Pressure overload
  • Statin

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Atorvastatin, valsartan, and n-acetylcysteine prevent cardiac hypertrophy and overexpression of myocardin in pressure-overloaded rat heart. / Chiu, Chiung Zuan; Wang, Bao Wei; Shyu, Kou Gi.

In: Acta Cardiologica Sinica, Vol. 28, No. 4, 12.2012, p. 286-296.

Research output: Contribution to journalArticle

@article{99ae3a76c99d4a1f971633e79e56bb67,
title = "Atorvastatin, valsartan, and n-acetylcysteine prevent cardiac hypertrophy and overexpression of myocardin in pressure-overloaded rat heart",
abstract = "Background: The use of statin has emerged as a beneficial treatment for cardiac hypertrophy.Myocardin, a cardiac restricted gene, is up-regulated in the hypertrophic myocardium. However, the effect of statin on myocardin expression due to pressure overloaded cardiac hypertrophy is not well understood. Methods: To evaluate the effect of statin on myocardin expression and cardiac hypertrophy, infrarenal aortic banding was performed for 4 weeks in adult Sprague-Dawley rats to induce cardiac hypertrophy. Atorvastatin (30 mg/kg), valsartan (30 mg/kg), N-acetylcysteine (NAC; 250 mg/kg), and the above three agents combined were given daily after surgery. Results: After aortic banding for 4 weeks, the heart weight, the ratio of heart/body weight, and mean arterial pressure (MAP) increased significantly. However, echocardiography showed concentric hypertrophy after aortic banding. Elevated MAP and increased wall thickness and heart weight were reversed after treatment with atorvastatin, valsartan, NAC, and a combination of the three agents. Myocardin, myosin heavy chain (MHC), brain natriuretic peptide (BNP) proteins, myocardin mRNA, angiotensin II (AngII), and superoxide dismutase (SOD) expressions were up-regulated in the banding group, which were inhibited by atorvastatin, valsartan, NAC, and the three agents combined. Increased immunohistochemical labelings of myocardin and MHC in the ventricular myocardium were observed in the banding group, and again atorvastatin, valsartan, or NAC reversed the labelings. Conclusion: Myocardin, MHC, BNP proteins, myocardin mRNA, AngII, and SOD expressions were up-regulated in the rat model of pressure-overloaded cardiac hypertrophy. Treatment with atorvastatin, valsartan, NAC, or three agents put together is associated with a reversal of abnormal regulation of myocardin in the hypertrophic myocardium.",
keywords = "Aortic banding, Cardiac hypertrophy, Myocardin, Pressure overload, Statin",
author = "Chiu, {Chiung Zuan} and Wang, {Bao Wei} and Shyu, {Kou Gi}",
year = "2012",
month = "12",
language = "English",
volume = "28",
pages = "286--296",
journal = "Acta Cardiologica Sinica",
issn = "1011-6842",
publisher = "Republic of China Society of Cardiology",
number = "4",

}

TY - JOUR

T1 - Atorvastatin, valsartan, and n-acetylcysteine prevent cardiac hypertrophy and overexpression of myocardin in pressure-overloaded rat heart

AU - Chiu, Chiung Zuan

AU - Wang, Bao Wei

AU - Shyu, Kou Gi

PY - 2012/12

Y1 - 2012/12

N2 - Background: The use of statin has emerged as a beneficial treatment for cardiac hypertrophy.Myocardin, a cardiac restricted gene, is up-regulated in the hypertrophic myocardium. However, the effect of statin on myocardin expression due to pressure overloaded cardiac hypertrophy is not well understood. Methods: To evaluate the effect of statin on myocardin expression and cardiac hypertrophy, infrarenal aortic banding was performed for 4 weeks in adult Sprague-Dawley rats to induce cardiac hypertrophy. Atorvastatin (30 mg/kg), valsartan (30 mg/kg), N-acetylcysteine (NAC; 250 mg/kg), and the above three agents combined were given daily after surgery. Results: After aortic banding for 4 weeks, the heart weight, the ratio of heart/body weight, and mean arterial pressure (MAP) increased significantly. However, echocardiography showed concentric hypertrophy after aortic banding. Elevated MAP and increased wall thickness and heart weight were reversed after treatment with atorvastatin, valsartan, NAC, and a combination of the three agents. Myocardin, myosin heavy chain (MHC), brain natriuretic peptide (BNP) proteins, myocardin mRNA, angiotensin II (AngII), and superoxide dismutase (SOD) expressions were up-regulated in the banding group, which were inhibited by atorvastatin, valsartan, NAC, and the three agents combined. Increased immunohistochemical labelings of myocardin and MHC in the ventricular myocardium were observed in the banding group, and again atorvastatin, valsartan, or NAC reversed the labelings. Conclusion: Myocardin, MHC, BNP proteins, myocardin mRNA, AngII, and SOD expressions were up-regulated in the rat model of pressure-overloaded cardiac hypertrophy. Treatment with atorvastatin, valsartan, NAC, or three agents put together is associated with a reversal of abnormal regulation of myocardin in the hypertrophic myocardium.

AB - Background: The use of statin has emerged as a beneficial treatment for cardiac hypertrophy.Myocardin, a cardiac restricted gene, is up-regulated in the hypertrophic myocardium. However, the effect of statin on myocardin expression due to pressure overloaded cardiac hypertrophy is not well understood. Methods: To evaluate the effect of statin on myocardin expression and cardiac hypertrophy, infrarenal aortic banding was performed for 4 weeks in adult Sprague-Dawley rats to induce cardiac hypertrophy. Atorvastatin (30 mg/kg), valsartan (30 mg/kg), N-acetylcysteine (NAC; 250 mg/kg), and the above three agents combined were given daily after surgery. Results: After aortic banding for 4 weeks, the heart weight, the ratio of heart/body weight, and mean arterial pressure (MAP) increased significantly. However, echocardiography showed concentric hypertrophy after aortic banding. Elevated MAP and increased wall thickness and heart weight were reversed after treatment with atorvastatin, valsartan, NAC, and a combination of the three agents. Myocardin, myosin heavy chain (MHC), brain natriuretic peptide (BNP) proteins, myocardin mRNA, angiotensin II (AngII), and superoxide dismutase (SOD) expressions were up-regulated in the banding group, which were inhibited by atorvastatin, valsartan, NAC, and the three agents combined. Increased immunohistochemical labelings of myocardin and MHC in the ventricular myocardium were observed in the banding group, and again atorvastatin, valsartan, or NAC reversed the labelings. Conclusion: Myocardin, MHC, BNP proteins, myocardin mRNA, AngII, and SOD expressions were up-regulated in the rat model of pressure-overloaded cardiac hypertrophy. Treatment with atorvastatin, valsartan, NAC, or three agents put together is associated with a reversal of abnormal regulation of myocardin in the hypertrophic myocardium.

KW - Aortic banding

KW - Cardiac hypertrophy

KW - Myocardin

KW - Pressure overload

KW - Statin

UR - http://www.scopus.com/inward/record.url?scp=84872716770&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84872716770&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:84872716770

VL - 28

SP - 286

EP - 296

JO - Acta Cardiologica Sinica

JF - Acta Cardiologica Sinica

SN - 1011-6842

IS - 4

ER -